AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

such as those produced by AstraZeneca and Johnson & Johnson, were working with a platform for vaccine candidates that had already been tested against other infectious diseases. By contrast, mRNA ...

MRNA), Merck (NYSE:MRK), and AstraZeneca (AZN), according to a recent research note from Morgan Stanley. Last year, Moderna (NASDAQ:MRNA) made headlines with its individualized mRNA cancer vaccine ...

The US$2 million (A$3.2 million) prize will help to accelerate the use of Vaxxas' high-density microarray patch (HD-MAP) technology to administer mRNA vaccines manufactured at UQ's BASE facility.

The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...